00017570972022-01-012022-06-300001757097country:US2022-06-300001757097country:US2021-12-310001757097cntg:EffectOfRevisionOfFinancialStatementsMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2022-07-012022-07-010001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2022-04-012022-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2022-01-012022-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2021-04-012021-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2021-01-012021-12-310001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2021-01-012021-06-300001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2020-01-012020-12-310001757097cntg:UnallocatedAmountsShareBasedPaymentsMember2019-01-012019-12-310001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2022-04-012022-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2022-01-012022-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2021-04-012021-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2021-01-012021-12-310001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2021-01-012021-06-300001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2020-01-012020-12-310001757097cntg:UnallocatedAmountsDepreciationAndAmortizationMember2019-01-012019-12-310001757097srt:ScenarioPreviouslyReportedMember2022-01-012022-03-3100017570972022-01-012022-03-310001757097srt:ScenarioPreviouslyReportedMember2021-07-012021-09-3000017570972021-07-012021-09-300001757097srt:ScenarioPreviouslyReportedMember2021-04-012021-06-300001757097srt:ScenarioPreviouslyReportedMember2021-01-012021-12-310001757097srt:ScenarioPreviouslyReportedMember2021-01-012021-09-3000017570972021-01-012021-09-300001757097srt:ScenarioPreviouslyReportedMember2021-01-012021-03-3100017570972021-01-012021-03-310001757097srt:ScenarioPreviouslyReportedMember2020-01-012020-12-3100017570972020-01-012020-12-310001757097cntg:IfrsCorporateMember2020-01-012020-12-310001757097cntg:IfrsCorporateMember2019-01-012019-12-310001757097srt:ScenarioPreviouslyReportedMember2019-01-012019-12-3100017570972019-01-012019-12-310001757097cntg:UnallocatedAmountsOneOffCostMember2022-04-012022-06-300001757097cntg:UnallocatedAmountsOneOffCostMember2022-01-012022-06-3000017570972022-06-300001757097srt:ScenarioPreviouslyReportedMember2022-03-3100017570972022-03-310001757097srt:ScenarioPreviouslyReportedMember2021-12-3100017570972021-12-310001757097srt:ScenarioPreviouslyReportedMember2021-09-3000017570972021-09-300001757097srt:ScenarioPreviouslyReportedMember2021-06-3000017570972021-06-300001757097srt:ScenarioPreviouslyReportedMember2021-03-3100017570972021-03-3100017570972021-01-010001757097srt:ScenarioPreviouslyReportedMember2020-12-3100017570972020-12-310001757097srt:ScenarioPreviouslyReportedMember2019-12-3100017570972019-12-310001757097srt:ScenarioPreviouslyReportedMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMember2022-04-012022-06-300001757097ifrs-full:OperatingSegmentsMember2022-01-012022-06-300001757097ifrs-full:OperatingSegmentsMember2021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMember2021-01-012021-12-310001757097ifrs-full:OperatingSegmentsMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMember2020-01-012020-12-310001757097ifrs-full:OperatingSegmentsMember2019-01-012019-12-310001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2022-04-012022-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2022-04-012022-06-300001757097cntg:IfrsCorporateMember2022-04-012022-06-3000017570972022-04-012022-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2022-01-012022-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2022-01-012022-06-300001757097cntg:IfrsCorporateMember2022-01-012022-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2021-04-012021-06-300001757097cntg:IfrsCorporateMember2021-04-012021-06-3000017570972021-04-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2021-01-012021-12-310001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2021-01-012021-12-310001757097ifrs-full:OperatingSegmentsMembercntg:Covid19Member2021-01-012021-12-310001757097cntg:IfrsCorporateMember2021-01-012021-12-3100017570972021-01-012021-12-310001757097ifrs-full:OperatingSegmentsMembercntg:PharmaceuticalSegmentMember2021-01-012021-06-300001757097ifrs-full:OperatingSegmentsMembercntg:DiagnosticsSegmentMember2021-01-012021-06-300001757097cntg:IfrsCorporateMember2021-01-012021-06-3000017570972021-01-012021-06-30iso4217:EURiso4217:USDiso4217:EURxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the date of December 22, 2022

Commission File Number 001-39124

Centogene N.V.

(Translation of registrant’s name into English)

Am Strande 7

18055 Rostock

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F.... Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Centogene N.V.

On December 22, 2022, Centogene N.V. (the “Company”) issued a press release reporting its financial results for the second quarter and first half of 2022 and 2021. A copy of the press release is attached hereto as Exhibit 99.1.

Attached hereto as Exhibits 99.2 and 99.3 are also the unaudited condensed interim financial statements of the Company for the second quarter and first half of 2022 and 2021 and risk factors on claims audits, capital raising and leverage, respectively. All exhibits attached hereto are incorporated by reference herein.

Exhibit 99.1 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the U.S. Securities Act of 1933, as amended, or the Exchange Act.

Exhibits 99.2 and 99.3 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form S-8 (Registration Number 333-234551) of the Company and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

2

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CENTOGENE N.V.

Date: December 22, 2022

By:

/s/ Jose Miguel Coego Rios

Name:

Jose Miguel Coego Rios

Title:

Chief Financial Officer

3

Exhibit Index

Exhibit

    

Description of Exhibit

99.1

Press Release dated December 22, 2022

99.2

Unaudited Condensed Consolidated Interim Financial Statements as of and for the Second Quarter and First Half ended June 30, 2022

99.3

Risk Factors on Claims Audits, Capital Raising and Leverage

4